Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA

Executive Summary

FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.

You may also be interested in...

US FDA's Regulatory Pipeline Includes DTC, Inspection Requirement Updates

Additionally, potential regulation to require clinical study sponsors to promptly report suspected data falsification seems to have found new life after being listed as inactive in July update of the Unified Agenda.

No 12-Year Exclusivity In US FDA's NDA-To-BLA Switch

The US Food and Drug Administration has published new draft guidance describing how it plans to take certain protein products that have been approved through Food, Drug and Cosmetic Act (FDCA) processes like the new drug application (NDA) pathway and move them over to the biologics license application (BLA) process1.

Biologic Product Exclusivity Decisions Will Involve Sponsor Dialogue, FDA Says

While FDA has laid out the types of information it wants sponsors to provide, agency acknowledges it cannot easily write guidance stating the extent of structural changes to a molecule that would justify a new period of exclusivity.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts